About this item:

197 Views | 182 Downloads

Author Notes:

Correspondence to: Harriet L. Robinson; Email: hrobinson@geovax.com

We would like to thank Susan Reuland for expert administrative assistance.

Michael Hellerstein, Yongxian Xu and Harriet Robinson are employees of GeoVax, Inc., a compmany that is developing GEO-D03 as a prime for a commercial DNA/MVA HIV vaccine.

Subject:

Research Funding:

This research was supported an Integrated Preclinical/Clinical AIDS Vaccine Development program project from the US Public Health Service, U19AI074073.

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Biotechnology & Applied Microbiology
  • Immunology
  • BIOTECHNOLOGY & APPLIED MICROBIOLOGY
  • IMMUNOLOGY
  • DNA vaccine
  • HIV vaccine
  • GEO-D03 DNA vaccine
  • GM-CSF adjuvant
  • HIV virus-like particles
  • MYELOID SUPPRESSOR-CELLS
  • IMMUNE-RESPONSE
  • DNA/MVA VACCINE
  • IMMUNOGENICITY
  • EXPRESSION
  • TYPE-1
  • IDENTIFICATION
  • PREVENTION
  • CHALLENGE
  • INFECTION

Co-expression of HIV-1 virus-like particles and granulocyte-macrophage colony stimulating factor by GEO-D03 DNA vaccine

Tools:

Journal Title:

Human Vaccines and Immunotherapeutics

Volume:

Volume 8, Number 11

Publisher:

, Pages 1654-1658

Type of Work:

Article | Final Publisher PDF

Abstract:

Here, we report on GEO-D03, a DNA vaccine that co-expresses non-infectious HIV -1 virus-like particles (VLPs) and the human cytokine, granulocyte- macrophage colony-stimulating factor (GM-CSF). The virus-like particles display the native gp160 form of the HIV -1 Envelope glycoprotein (Env) and are designed to elicit antibody against the natural form of Env on virus and virus-infected cells. The DNA-expressed HIV Gag, Pol and Env proteins also have the potential to elicit virus-specific CD4 and CD8 T cells. The purpose of the co-expressed GM-CSF is to target a cytokine that recruits, expands and differentiates macrophages and dendritic cells to the site of VLP expression. The GEO-D03 DNA vaccine is currently entered into human trials as a prime for a recombinant modified vaccinia Ankara (MVA) boost. In preclinical studies in macaques using an SIV prototype vaccine, this vaccination regimen elicited both anti-viral T cells and antibody, and provided 70% protection against acquisition during 12 weekly rectal exposures with a heterologous SIV . Higher avidity of the Env-specific Ab for the native form of the Env in the challenge virus correlated with lower likelihood of SIV infection.

Copyright information:

© 2012 Landes Bioscience.

This is an Open Access work distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/).

Creative Commons License

Export to EndNote